Seres Therapeutics' SER-155 Shows Early Promise in Treating ICI-Related Enterocolitis
Event summary
- 80% of SER-155 recipients achieved immunosuppressive-free clinical response in diarrhea symptoms at Day 15.
- Study conducted by Memorial Sloan Kettering Cancer Center involved 15 patients with moderate-to-severe irEC.
- SER-155 was well tolerated with no drug-related serious adverse events observed.
- Data suggests SER-155 could repair mucosal epithelial barrier and reduce gastrointestinal inflammation.
The big picture
Seres Therapeutics' early clinical data for SER-155 highlights a potential non-immunosuppressive treatment for immune checkpoint inhibitor-related enterocolitis (irEC), addressing a significant unmet need in cancer therapy. The results could position Seres as a key player in the growing market for microbiome-based therapeutics, particularly in managing adverse effects of immunotherapy.
What we're watching
- Partnership Strategy
- How Seres Therapeutics will leverage potential partnerships to advance SER-155 development.
- Clinical Development
- The pace at which Seres can secure funding and initiate Phase 2 studies for SER-155 in allo-HCT.
- Market Expansion
- Whether SER-155's success in irEC could pave the way for applications in other inflammatory diseases.
Related topics